news aktuell GmbH

TRENTAR MOBILITY GmbH enters the German market and acquires ORTEN Group – strategic partnership for future technologies and growth

Dela
  • ORTEN Group remains independent and will serve as TRENTAR MOBILITY’s growth platform in Europe
  • Expansion of competencies in future mobility solutions, along with broader access to investments, markets, and technological expertise
  • TRENTAR MOBILITY is exploring additional strategic growth opportunities and is interested in acquiring further manufacturers in Europe for growth in the future mobility sector

Bernkastel-Kues/Mumbai, May 5, 2025 – ORTEN Group (“ORTEN”), a specialist in customized commercial vehicle solutions, is strategically repositioning itself: The German company will become part of TRENTAR MOBILITY GmbH (“TRENTAR MOBILITY”). TRENTAR Group invests in diversified future technologies by drone manufacturing and services, IT / software and mobility solutions.

The change in ownership opens new horizons for ORTEN – shaped by digitalization, investments in future technologies, and international growth. At the same time, ORTEN remains entrepreneurially independent with strong roots in Germany and 100 years of company history. TRENTAR MOBILITY is taking over the entire ORTEN Group, consisting of ORTEN Fahrzeugbau, Christophorus Nutzfahrzeuge, GeBoKit, and ETW Electric Trucks, with around 100 employees at the sites in Bernkastel-Kues, Wittlich-Wengerohr, and Rothnaußlitz. Existing sites and jobs will be preserved and further developed. In addition, ORTEN aims under the new ownership to further strengthen and expand its market presence across Europe and in particular in Germany, Austria, and Switzerland.

Managing Director and Shareholder Robert Orten, who successfully led the company for more than 48 years, will continue to accompany the transition as Managing Director until September 2025 and will subsequently serve as an advisor to the group.

"It was very important to me to find a stable and future-oriented succession solution – for our employees, our company, and our partners," says Robert Orten. "With TRENTAR MOBILITY, we have deliberately chosen a strong, majority family-owned partner who not only respects our history but also actively creates new opportunities for our development as well as the preservation of the ORTEN brand."

TRENTAR MOBILITY GmbH is part of TRENTAR Group, a broader network of companies focused on sustainable growth and innovation in the field of new mobility and future technologies such as breakthrough KPITs’ Sodium Ion Battery Technology. TRENTAR Group also bought stakes in start-ups manufacturing drones and providing services utilizing drones and other aerial systems such as “R-Fly” and “GarudaUAV Soft Solutions”. The aim is to drive sustainable technological innovation in mobility and logistics globally. Europe plays a central role as a strategic growth market, and the Group is actively exploring additional acquisitions in the vehicle manufacturing and mobility sectors.

"With the acquisition of ORTEN, we are deliberately investing in technological expertise, entrepreneurial spirit, and regional strength. ORTEN’s 100-year legacy, its commitment to people, the environment, and society, and its strong regional roots deeply resonate with our own corporate values. Europe is a central part to our strategic development – not as a market of the past, but as a key partner for the future. This is why we aim to grow here strategically and are also interested in further acquisitions. Our goal is to drive innovation, open new markets, and build on stability, trust, and progress together with the existing management team and the new CEO Tarkeshwar Rao," explains Subodh Menon, Founder of TRENTAR MOBILITY GmbH and TRENTAR Group.

The purchase price was not disclosed. Further details about ORTEN can be found at: https://www.orten-fahrzeugbau.de/en/

Media contact

Rosenberg Strategic Communications GmbH & Co. KG
Jorg Keller

+49 151 61527741­ | j.keller@rosenbergsc.com

Bilder

Följ news aktuell GmbH

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från news aktuell GmbH

Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 12:34:15 CET | Press Release

Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions

Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release

Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye